- Home
- AKTX vs PIII Comparison
AKTX vs PIII Comparison
Compare AKTX & PIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- PIII
- Stock Information
- Founded
- AKTX N/A
- PIII 2015
- Country
- AKTX United States
- PIII United States
- Employees
- AKTX N/A
- PIII N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- PIII Medical/Nursing Services
- Sector
- AKTX Health Care
- PIII Health Care
- Exchange
- AKTX Nasdaq
- PIII Nasdaq
- Market Cap
- AKTX 35.7M
- PIII 28.6M
- IPO Year
- AKTX N/A
- PIII N/A
- Fundamental
- Price
- AKTX $0.76
- PIII $8.38
- Analyst Decision
- AKTX Strong Buy
- PIII Strong Buy
- Analyst Count
- AKTX 2
- PIII 3
- Target Price
- AKTX $3.30
- PIII $17.50
- AVG Volume (30 Days)
- AKTX 91.6K
- PIII 7.0K
- Earning Date
- AKTX 08-13-2025
- PIII 11-11-2025
- Dividend Yield
- AKTX N/A
- PIII N/A
- EPS Growth
- AKTX N/A
- PIII N/A
- EPS
- AKTX N/A
- PIII N/A
- Revenue
- AKTX N/A
- PIII $1,461,823,000.00
- Revenue This Year
- AKTX N/A
- PIII N/A
- Revenue Next Year
- AKTX N/A
- PIII $9.46
- P/E Ratio
- AKTX N/A
- PIII N/A
- Revenue Growth
- AKTX N/A
- PIII 4.20
- 52 Week Low
- AKTX $0.57
- PIII $5.80
- 52 Week High
- AKTX $3.85
- PIII $26.99
- Technical
- Relative Strength Index (RSI)
- AKTX 37.47
- PIII 59.01
- Support Level
- AKTX $0.75
- PIII $8.46
- Resistance Level
- AKTX $0.89
- PIII $8.90
- Average True Range (ATR)
- AKTX 0.07
- PIII 0.32
- MACD
- AKTX 0.01
- PIII -0.02
- Stochastic Oscillator
- AKTX 57.86
- PIII 49.07
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.